SilverCrest Metals
SILV
Collegium Pharmaceutical
COLL
Cars.com
CARS
Hutchmed (China)
HCM
Halozyme Therapeutics
HALO
(Q3)Sep 28, 2024 | (Q2)Jun 29, 2024 | (Q1)Mar 30, 2024 | (FY)Dec 30, 2023 | (Q4)Dec 30, 2023 | (Q3)Sep 30, 2023 | (Q2)Jul 1, 2023 | (Q1)Apr 1, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 1.65%3.47B | 1.48%4.25B | 2.90%3.39B | 2.47%14.56B | -8.65%3.66B | 4.32%3.41B | 7.21%4.18B | 9.10%3.3B | 11.57%14.2B | 20.70%4.01B |
Operating revenue | 1.65%3.47B | 1.48%4.25B | 2.90%3.39B | 2.47%14.56B | -8.65%3.66B | 4.32%3.41B | 7.21%4.18B | 9.10%3.3B | 11.57%14.2B | 20.70%4.01B |
Cost of revenue | 0.75%2.18B | 0.79%2.69B | 2.10%2.17B | 1.03%9.33B | -10.44%2.37B | 2.68%2.16B | 6.07%2.67B | 8.22%2.13B | 11.86%9.23B | 20.20%2.64B |
Gross profit | 3.20%1.29B | 2.70%1.56B | 4.35%1.22B | 5.15%5.23B | -5.17%1.29B | 7.26%1.25B | 9.27%1.51B | 10.73%1.17B | 11.06%4.97B | 21.69%1.36B |
Operating expense | 6.19%965.85M | 4.05%994.17M | 3.49%957.73M | 5.99%3.75B | -4.54%958.83M | 5.84%909.57M | 10.94%955.44M | 13.94%925.47M | 11.57%3.54B | 21.38%1B |
Selling and administrative expenses | 4.03%852.3M | 3.72%884.9M | 3.04%853.44M | 5.07%3.36B | -5.94%855.55M | 6.11%819.31M | 9.68%853.16M | 12.75%828.24M | 10.13%3.19B | 20.94%909.6M |
Depreciation amortization depletion | 25.80%113.55M | 6.83%109.27M | 7.26%104.29M | 14.57%393.05M | 8.92%103.27M | 3.47%90.26M | 22.70%102.28M | 25.23%97.23M | 26.99%343.06M | 25.71%94.82M |
-Depreciation and amortization | 25.80%113.55M | 6.83%109.27M | 7.26%104.29M | 14.57%393.05M | 8.92%103.27M | 3.47%90.26M | 22.70%102.28M | 25.23%97.23M | 26.99%343.06M | 25.71%94.82M |
Operating profit | -4.78%324.6M | 0.38%561.46M | 7.64%263.13M | 3.06%1.48B | -6.95%334.24M | 11.26%340.91M | 6.53%559.33M | 0.06%244.44M | 9.81%1.43B | 22.57%359.21M |
Net non-operating interest income expense | -45.46%-13.88M | 5.92%-11.61M | 6.14%-11.9M | -51.83%-46.51M | -16.67%-11.95M | -53.21%-9.54M | -73.92%-12.34M | -79.37%-12.68M | -15.12%-30.63M | -56.54%-10.24M |
Non-operating interest expense | 45.46%13.88M | -5.92%11.61M | -6.14%11.9M | 51.83%46.51M | 16.67%11.95M | 53.21%9.54M | 73.92%12.34M | 79.37%12.68M | 15.12%30.63M | 56.54%10.24M |
Other net income (expense) | ||||||||||
Income before tax | -6.23%310.72M | 0.52%549.85M | 8.40%251.22M | 2.00%1.43B | -7.65%322.29M | 10.39%331.37M | 5.61%546.99M | -2.30%231.76M | 9.70%1.4B | 21.80%348.97M |
Income tax | -9.31%69.25M | -0.88%124.65M | 9.01%53.06M | 3.03%325.18M | -4.76%74.38M | 15.62%76.37M | 3.54%125.76M | -2.64%48.67M | 11.53%315.6M | 19.83%78.1M |
Net income | -5.31%241.47M | 0.94%425.2M | 8.24%198.17M | 1.70%1.11B | -8.48%247.9M | 8.91%255M | 6.24%421.23M | -2.21%183.09M | 9.19%1.09B | 22.38%270.87M |
Net income continuous Operations | -5.31%241.47M | 0.94%425.2M | 8.24%198.17M | 1.70%1.11B | -8.48%247.9M | 8.91%255M | 6.24%421.23M | -2.21%183.09M | 9.19%1.09B | 22.38%270.87M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -5.31%241.47M | 0.94%425.2M | 8.24%198.17M | 1.70%1.11B | -8.48%247.9M | 8.91%255M | 6.24%421.23M | -2.21%183.09M | 9.19%1.09B | 22.38%270.87M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -5.31%241.47M | 0.94%425.2M | 8.24%198.17M | 1.70%1.11B | -8.48%247.9M | 8.91%255M | 6.24%421.23M | -2.21%183.09M | 9.19%1.09B | 22.38%270.87M |
Basic earnings per share | -3.85%0.45 | 2.60%0.79 | 10.84%0.368 | 3.78%2.03 | -6.53%0.458 | 10.90%0.468 | 8.45%0.77 | 0.00%0.332 | 12.54%1.956 | 25.64%0.49 |
Diluted earnings per share | -3.86%0.448 | 2.61%0.786 | 10.91%0.366 | 3.91%2.018 | -6.17%0.456 | 10.95%0.466 | 8.50%0.766 | 0.00%0.33 | 12.78%1.942 | 25.91%0.486 |
Dividend per share | 6.80%0.22 | 6.80%0.22 | 6.80%0.22 | 11.96%0.824 | 11.96%0.206 | 11.96%0.206 | 11.96%0.206 | 11.96%0.206 | 76.92%0.736 | 76.92%0.184 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |